Amgen – Ultimovacs Pronounces the Appointment of Ton Berkien as Chief Enterprise Officer
Get inside Wall Street with StreetInsider Premium. Declare your 1-week free trial right here.
OSLO, Norway–(BUSINESS WIRE)–
Ultimovacs ASA (“Ultimovacs”, ticker ULTIMO), right now introduced that Ton Berkien will be part of Ultimovacs’ administration crew as Chief Enterprise Officer (CBO), efficient December 1, 2020. Mr. Berkien will be part of Ultimovacs from his present place at Amgen as Director International Enterprise Improvement. At Ultimovacs, he’ll lead all enterprise and company growth efforts and proceed to take care of and foster connections with main biotechnology and pharmaceutical firms.
“In the last months, Ultimovacs has strengthened its corporate and clinical development position having launched multiple mid-stage clinical trials and established a solid financial runway. As the clinical trials continue to advance, now is the right time to expand our management team and place a greater focus on our business development efforts,” commented Carlos de Sousa, Chief Govt Officer at Ultimovacs. “As a biopharmaceutical industry professional with an extensive international business development background, insights on corporate financing and years of experience in leading and executing business transactions, we welcome Ton to Ultimovacs’ management team and are enthusiastic to collaborate with him and continue to build value for the Company, our shareholders and patients in need of novel therapeutic options.”
“Over the years, Ultimovacs’ lead therapeutic cancer vaccine program, UV1, has garnered interest from key opinion leaders, physicians and pharmaceutical companies based on its encouraging potential in a range of solid tumor cancers,” acknowledged Ton Berkien, Chief Enterprise Officer at Ultimovacs. “As Ultimovacs moves towards its next value inflection points, supported by a number of mid-stage clinical trials, together, we will build on the Company’s well-established scientific foundation to identify new, strategic opportunities and global partnerships. I greatly look forward to joining the accomplished management team and contributing to Ultimovacs’ ongoing growth and success as a biotechnology company developing novel immunotherapies against cancer.”
Ton Berkien joins Ultimovacs with over 15 years of expertise in strategic enterprise growth and company finance within the biopharmaceutical business. His most up-to-date place was at Amgen as Director International Enterprise Improvement – Transactions, a place he assumed in August 2019 following the acquisition of Nuevolution, a Danish small molecule growth firm, at which he led the industrial and enterprise actions as Chief Enterprise Officer. Throughout his tenure at Nuevolution, Mr. Berkien contributed to various company achievements together with supporting the corporate’s profitable itemizing onto Nasdaq OMX Stockholm, executing a program out-licensing take care of Almirall in addition to drug discovery collaborations with Janssen Biotech and Amgen. Previous to this, Mr. Berkien was appearing Head of Company Improvement/M&A at Takeda/Nycomed, the place he accomplished a number of M&A transactions in america, Europe and in varied rising development markets resembling China, Brazil, India and Colombia. Earlier in his profession, Mr. Berkien additionally held senior supervisor positions at PricewaterhouseCoopers, Rijnconsult, KPMG and Gilde Funding Administration.
Mr. Berkien is at the moment a board member of the Nordic Pharma Licensing Group. Earlier than beginning his profession, he obtained a bachelor’s diploma in Economics from the Saxion College of Utilized Science within the Netherlands and an LSid from PwC/Harvard Enterprise College/IMD. Mr. Berkien is a Dutch and Swedish citizen and is predicated in Sweden.
About Ultimovacs
Ultimovacs’ UV1 common most cancers vaccine candidate leverages the excessive prevalence of the human telomerase (hTERT) to be efficient throughout the dynamic levels of the tumor’s development and its microenvironment. By directing the immune system to hTERT antigens which can be current in over 80% of all cancers, UV1 drives CD4 helper T cells to the tumor with the purpose of activating an immune system cascade to extend anti-tumor responses. Ultimovacs’ technique is to clinically show UV1’s affect in a variety of cancers and in a number of immunotherapy combos whereas increasing our pipeline of most cancers vaccine therapies, satisfied {that a} common method may be the important thing to attaining higher outcomes for sufferers.
For additional data, please see www.ultimovacs.com.
View supply model on businesswire.com: https://www.businesswire.com/information/residence/20201123006009/en/
Carlos de Sousa, Chief Govt Officer
Electronic mail: carlos.desousa@ultimovacs.com
Telephone: +47 908 92507
Hans Vassgård Eid, Chief Monetary Officer
Electronic mail: hans.eid@ultimovacs.com
Telephone: +47 482 48632
Supply: Ultimovacs ASA
